Skip to main content
Gary Lyman, MD, Oncology, Kirkland, WA

GaryHerbertLymanMDMPH, FASCO, FACP, FRCP

Oncology • Kirkland, WA

Hematologic Oncology

Adjunct Professor of Medicine, Duke University, Durham NC Fred Hutchinson Cancer Center, Public Health Sciences

Join to view full profile

Dr. Lyman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lyman's full profile

Already have an account?

  • Office

    210 MARKET STREET
    Suite 303
    Kirkland, WA 98033
    Phone+1 919-724-0038
    Fax+1 919-724-0038

Summary

  • Previously Director of Comparative Effectiveness Research at the Duke Cancer Institute; Senior Fellow Duke Center for Clinical Health Policy Research. Received undergraduate and medical degree from SUNY Buffalo, Internal Medicine residency at UNC Chapel Hill, Clinical Hematology/Oncology Fellowship at Roswell Park and Postdoctoral Fellowship in Biostatistics at the Harvard School of Public Health & Dana Farber Cancer Center. Previously Professor of Medicine and Chief of Medicine at the Moffitt Cancer Center as well as Prof of Epidemiology/Biostatistics and Associate Chair Medicine at USF. Held Thomas Ordway Endowed Chair & Cancer Center Director Albany Medical College & Prof Epidemiology/Biostatistics SUNY Albany and Prof of Medicine, Associate Cancer Center Director and Director of Health Services and Outcomes Research at University of Rochester. Fellow of ASCO, the American College of Physicians, and the Royal College of Physicians. Editor-In-Chief of Cancer Investigation and on Editorial Board of several oncology specialty journals. Serves on Board of Directors of the Hope Foundation for Cancer Research. Dr Lyman states "I have been extremely privileged to work with some of worlds best biostatisticians/trialists over years including postdoctoral for the fellowship with Prof Marvin Zelen at Harvard, Visiting Prof with Prof Stuart Pocock at London School of Hygiene &Tropical Medicine & Prof Doug Altman at Centre for Health Statistics at Oxford now in Public Health Sciences at Fred Hutch enabling my listing among the top 1% of most highly cited investigators by Web of Science for 7 consecutive years with nearly 100,000 citations. Thank you all. https://en.wikipedia.org/wiki/Gary_Herbert_Lyman
    https://scholars.duke.edu/person/gary.lyman

Education & Training

  • Harvard School of Public Health
    Harvard School of Public HealthPost-Doctoral Fellowship, 1981 - 1982
  • University at Buffalo
    University at BuffaloFellowship, Hematology and Medical Oncology, 1974 - 1977
  • University of North Carolina Hospitals
    University of North Carolina HospitalsResidency, Internal Medicine, 1972 - 1974
  • Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
    Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1972

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1972 - 2025
  • WA State Medical License
    WA State Medical License 2014 - 2025
  • NY State Medical License
    NY State Medical License 1974 - 2009
  • FL State Medical License
    FL State Medical License 1977 - 2002
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Distinguished Emeritus Member American Society of Hematology, 1976-2023
  • America's Top Doctors Castle Connolly, 2005-2015
  • America's Top Doctors for Cancer Castle Connolly, 2005-2015
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Aligning Cancer Clinical Trials with Cancer Burden  
    Nicole M Kuderer, Gary H Lyman, JAMA Oncology
  • Association of Generic Imatinib Availability and Pricing with Trends in Tyrosine Kinase Inhibitor Use in Patients with Chronic Myelogenous Leukemia  
    Gary Lyman, MD, JAMA Oncology

Abstracts/Posters

  • Health Care Costs Associated with Contemporary Chronic Myelogenous Leukemia (CML) Therapy Compared to Other Hematologic Malignancies (HEM)
    Gary H. Lyman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Cancer Associated Thrombosis Is Associated with Higher Mortality across All Khorana Score Risk Levels
    Gary H. Lyman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Meta-Analysis and Cost-Effectiveness Analysis of Low-Dose Direct Oral Anticoagulant for the Prevention of Cancer Associated Thrombosis
    Gary H. Lyman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • What Biosimilars Mean for Your Hematology/Oncology Practice 
    60th American Society of Hematology Annual Meeting - 11/30/2018
  • Paving the Way Forward: The Role of Post-Market Evidence Development, Education, and Guidance 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

  • Gary Herbert Lyman
    Gary Herbert LymanApril 21st, 2024
  • Risk of Chemotherapy-Induced Febrile Neutropenia in Intermediate-Risk Regimens: Clinical and Economic Outcomes of Granulocyte Colony-Stimulating Factor Prophylaxis
    Risk of Chemotherapy-Induced Febrile Neutropenia in Intermediate-Risk Regimens: Clinical and Economic Outcomes of Granulocyte Colony-Stimulating Factor ProphylaxisFebruary 1st, 2023
  • Conquer Cancer Announces 2023 Genitourinary Cancers Symposium Merit Awards
    Conquer Cancer Announces 2023 Genitourinary Cancers Symposium Merit AwardsJanuary 26th, 2023
  • Join now to see all

Professional Memberships

External Links

  • Wikipediahttps://en.wikipedia.org/wiki/Gary_Herbert_Lyman

Dr. Gary Lyman, Dr. Gary Lyman, MD, Dr. G Lyman, Dr. Gary Herbert Lyman